Nature Communications · 2018 · 22 citations · 27 references
Life SciencesGeneticsMolecular BiologyGene ExpressionSignal TransductionTranscriptional RegulationLimb DevelopmentMicrorna BiologyMicrorna-mediated RegulationSkeletal DevelopmentDisease-associated MicrornasLoss-of-function MutationsMicrorna Function In DifferentiationMicrorna In DevelopmentMicrorna Regulation In DevelopmentSkeletal Developmental DefectsSkeletal Dysplasia GeneticsSkeletal Dysplasia Mutations
Feingold syndrome is a skeletal dysplasia caused by loss-of-function mutations of either MYCN (type 1) or MIR17HG that encodes miR-17-92 microRNAs (type 2). Since miR-17-92 expression is transcriptionally regulated by MYC transcription factors, it has been postulated that Feingold syndrome type 1 and 2 may be caused by a common molecular mechanism. Here we show that Mir17-92 deficiency upregulates TGF-β signaling, whereas Mycn-deficiency downregulates PI3K signaling in limb mesenchymal cells. Genetic or pharmacological inhibition of TGF-β signaling efficiently rescues the skeletal defects caused by Mir17-92 deficiency, suggesting that upregulation of TGF-β signaling is responsible for the skeletal defect of Feingold syndrome type 2. By contrast, the skeletal phenotype of Mycn-deficiency is partially rescued by Pten heterozygosity, but not by TGF-β inhibition. These results strongly suggest that despite the phenotypical similarity, distinct molecular mechanisms underlie the pathoetiology for Feingold syndrome type 1 and 2.
27
STAR: ultrafast universal RNA-seq aligner
Alexander Dobin, Carrie Davis, Felix Schlesinger et al. · Bioinformatics · 2012 · 56.2K citations · Full text
A microRNA polycistron as a potential human oncogene
Lin He, J. Michael Thomson, Michael T. Hemann et al. · Nature · 2005 · 3.5K citations
c-Myc-regulated microRNAs modulate E2F1 expression
Kathryn A. O’Donnell, Erik A. Wentzel, Karen Zeller et al. · Nature · 2005 · 2.6K citations
Andrea Ventura, Amanda Young, Monte M. Winslow et al. · Cell · 2008 · 1.6K citations · Full text